STOCK TITAN

Armistice Capital, Steven Boyd file 9.89% stake in FibroGen (FGEN)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

FibroGen Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 400,000 shares of common stock, representing 9.89% of the class as of 12/31/2025. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund has the right to receive dividends or sale proceeds. Steven Boyd is identified as managing member of Armistice Capital and files jointly with the firm.

Positive

  • None.

Negative

  • None.

Insights

Armistice Capital reports a near-10% stake via a managed fund.

Armistice Capital is disclosed as investment manager to Armistice Capital Master Fund Ltd., which directly holds the 400,000 shares reported as 9.89% as of 12/31/2025. The filing clarifies voting and dispositive power is exercised by Armistice Capital under an Investment Management Agreement.

Disclosure notes the Master Fund "disclaims beneficial ownership" of the shares due to the manager arrangement while retaining economic rights; cash-flow treatment is described: the Master Fund "has the right to receive dividends from, or the proceeds from the sale of, the reported securities." Subsequent filings may detail any changes to percent ownership.

Joint filing and footnotes align with Rule 13d-1(k) joint reporting norms.

The statement is filed jointly by Armistice Capital and Steven Boyd and includes the required joint-filing acknowledgement dated 02/17/2026. It specifies shared voting and dispositive power of 400,000 shares.

For governance review, this level of disclosure signals a significant stake that must be tracked for future Schedule 13D/G amendments; the filing preserves manager-client distinctions by noting the Master Fund retains economic rights.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in FGEN?

Armistice Capital reports beneficial ownership of 400,000 shares, equal to 9.89% of common stock as of 12/31/2025. The filing attributes voting and dispositive power to Armistice Capital under its Investment Management Agreement.

Who holds the FGEN shares according to the filing?

The filing states that Armistice Capital Master Fund Ltd. is the direct holder of the shares, with Armistice Capital exercising voting and investment power as manager, and the Master Fund retaining rights to dividends and sale proceeds.

Does Steven Boyd personally own the reported FGEN shares?

Steven Boyd is disclosed as managing member of Armistice Capital and is included as a reporting person; the filing explains he may be deemed to beneficially own the shares through his role with Armistice Capital rather than direct ownership.

When was the joint filing for FGEN signed?

The joint Schedule 13G/A was signed by Steven Boyd on 02/17/2026. The ownership figures reported correspond to the period ending 12/31/2025, per the form header and Item 4 disclosure.

What voting and dispositive powers are reported for FGEN shares?

The reporting persons list 0 shares with sole voting power and 400,000 shares with shared voting power; sole dispositive power is 0 and shared dispositive power is 400,000, per Item 4.
Fibrogen Inc

NASDAQ:FGEN

FGEN Rankings

FGEN Latest News

FGEN Latest SEC Filings

FGEN Stock Data

39.28M
4.05M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO